Blefarospasmo (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Blefarospasmo" in Italian language version.

refsWebsite

Global rank Italian rank

30nih.gov

4^th place

9^th place

11doi.org

2^nd place

7^th place

10oadoi.org

799^th place

22^nd place

6archive.org

6^th place

8^th place

2books.google.com

3^rd place

14^th place

2web.archive.org

1^st place

1blepharospasm.org

low place

archive.org

NC. Tan, LL. Chan; EK. Tan, Hemifacial spasm and involuntary facial movements., in QJM, vol. 95, n. 8, agosto 2002, pp. 493-500, PMID 12145388.
S. Koh, J. Hosohata; Y. Tano, Bilateral upper eyelid ectropion associated with blepharospasm., in Br J Ophthalmol, vol. 90, n. 11, novembre 2006, pp. 1437-8, DOI:10.1136/bjo.2006.097089, PMID 17057180.
C. Colosimo, M. Chianese; M. Giovannelli; MF. Contarino; AR. Bentivoglio, Botulinum toxin type B in blepharospasm and hemifacial spasm., in J Neurol Neurosurg Psychiatry, vol. 74, n. 5, maggio 2003, p. 687, PMID 12700325.
J. Horwath-Winter, J. Bergloeff; I. Floegel; EM. Haller-Schober; O. Schmut, Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye., in Br J Ophthalmol, vol. 87, n. 1, gennaio 2003, pp. 54-6, PMID 12488263.
J. Ananth, E. Edelmuth; B. Dargan, Meige's syndrome associated with neuroleptic treatment., in Am J Psychiatry, vol. 145, n. 4, aprile 1988, pp. 513-5, PMID 2894781.
ES. Tolosa, C. Lai, Meige disease: striatal dopaminergic preponderance., in Neurology, vol. 29, n. 8, agosto 1979, pp. 1126-30, PMID 379689.

blepharospasm.org

Benign essential blepharospasm often begins with excessive blinking, eyelid spasms, twiches or tics., su blepharospasm.org. URL consultato il 5 settembre 2010.

books.google.com

William Pai-Dei Chen, Oculoplastic surgery: the essentials, Thieme, 15 giugno 2001, pp. 115–, ISBN 978-1-58890-027-2. URL consultato il 5 marzo 2011.
Alberto Albanese, I gangli motori e i disturbi del movimento, PICCIN, 1991, pp. 369–, ISBN 978-88-299-0911-7.

doi.org

dx.doi.org

K. Tanner, N. Roy; RM. Merrill; K. Kimber; C. Sauder; DR. Houtz; D. Doman; ME. Smith, Risk and Protective Factors for Spasmodic Dysphonia: A Case-Control Investigation., in J Voice, febbraio 2010, DOI:10.1016/j.jvoice.2009.09.004, PMID 20171836.
J. Xiao, Y. Zhao; RW. Bastian; JS. Perlmutter; BA. Racette; SD. Tabbal; M. Karimi; RC. Paniello; ZK. Wszolek; RJ. Uitti; JA. Van Gerpen, Novel THAP1 sequence variants in primary dystonia., in Neurology, vol. 74, n. 3, gennaio 2010, pp. 229-38, DOI:10.1212/WNL.0b013e3181ca00ca, PMID 20083799.
MA. van Steensel, RJ. Damstra; MV. Heitink; RS. Bladergroen; J. Veraart; PM. Steijlen; M. van Geel, Novel missense mutations in the FOXC2 gene alter transcriptional activity., in Hum Mutat, vol. 30, n. 12, dicembre 2009, pp. E1002-9, DOI:10.1002/humu.21127, PMID 19760751.
MS. LeDoux, Meige syndrome: what's in a name?, in Parkinsonism Relat Disord, vol. 15, n. 7, agosto 2009, pp. 483-9, DOI:10.1016/j.parkreldis.2009.04.006, PMID 19457699.
G. Defazio, M. Matarin; EL. Peckham; D. Martino; EM. Valente; A. Singleton; A. Crawley; MS. Aniello; F. Brancati; G. Abbruzzese; P. Girlanda, The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm., in Mov Disord, vol. 24, n. 4, marzo 2009, pp. 613-6, DOI:10.1002/mds.22471, PMID 19202559.
M. Hallett, C. Evinger; J. Jankovic; M. Stacy; M. Ali; A. Berardelli; RB. Daroff; G. Defazio; M. Delong; D. Eidelberg; C. Evinger, Update on blepharospasm: report from the BEBRF International Workshop., in Neurology, vol. 71, n. 16, ottobre 2008, pp. 1275-82, DOI:10.1212/01.wnl.0000327601.46315.85, PMID 18852443.
E. Tolosa, Y. Compta, Dystonia in Parkinson's disease., in J Neurol, 253 Suppl 7, dicembre 2006, pp. VII7-13, DOI:10.1007/s00415-006-7003-6, PMID 17131231.
JS. Yoon, JC. Kim; SY. Lee, Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm., in Korean J Ophthalmol, vol. 23, n. 3, settembre 2009, pp. 137-41, DOI:10.3341/kjo.2009.23.3.137, PMID 19794937.
R. Laskawi, The use of botulinum toxin in head and face medicine: an interdisciplinary field., in Head Face Med, vol. 4, 2008, p. 5, DOI:10.1186/1746-160X-4-5, PMID 18331633.
S. Koh, J. Hosohata; Y. Tano, Bilateral upper eyelid ectropion associated with blepharospasm., in Br J Ophthalmol, vol. 90, n. 11, novembre 2006, pp. 1437-8, DOI:10.1136/bjo.2006.097089, PMID 17057180.
Bhatia MS, Gupta R, Essential blepharospasm responding to haloperidol, in J Neuropsychiatry Clin Neurosci, vol. 18, n. 4, 2006, pp. 554–6, DOI:10.1176/appi.neuropsych.18.4.554, PMID 17135386.

nih.gov

ncbi.nlm.nih.gov

NJ. Moon, HI. Lee; JC. Kim, The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm., in J Korean Med Sci, vol. 21, n. 1, Feb 2006, pp. 131-5, PMID 16479079.
RA. Pagon, TC. Bird; CR. Dolan; K. Stephens; H. Miyajima, Aceruloplasminemia, PMID 20301666.
K. Tanner, N. Roy; RM. Merrill; K. Kimber; C. Sauder; DR. Houtz; D. Doman; ME. Smith, Risk and Protective Factors for Spasmodic Dysphonia: A Case-Control Investigation., in J Voice, febbraio 2010, DOI:10.1016/j.jvoice.2009.09.004, PMID 20171836.
J. Xiao, Y. Zhao; RW. Bastian; JS. Perlmutter; BA. Racette; SD. Tabbal; M. Karimi; RC. Paniello; ZK. Wszolek; RJ. Uitti; JA. Van Gerpen, Novel THAP1 sequence variants in primary dystonia., in Neurology, vol. 74, n. 3, gennaio 2010, pp. 229-38, DOI:10.1212/WNL.0b013e3181ca00ca, PMID 20083799.
MA. van Steensel, RJ. Damstra; MV. Heitink; RS. Bladergroen; J. Veraart; PM. Steijlen; M. van Geel, Novel missense mutations in the FOXC2 gene alter transcriptional activity., in Hum Mutat, vol. 30, n. 12, dicembre 2009, pp. E1002-9, DOI:10.1002/humu.21127, PMID 19760751.
MS. LeDoux, Meige syndrome: what's in a name?, in Parkinsonism Relat Disord, vol. 15, n. 7, agosto 2009, pp. 483-9, DOI:10.1016/j.parkreldis.2009.04.006, PMID 19457699.
G. Defazio, M. Matarin; EL. Peckham; D. Martino; EM. Valente; A. Singleton; A. Crawley; MS. Aniello; F. Brancati; G. Abbruzzese; P. Girlanda, The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm., in Mov Disord, vol. 24, n. 4, marzo 2009, pp. 613-6, DOI:10.1002/mds.22471, PMID 19202559.
M. Hallett, C. Evinger; J. Jankovic; M. Stacy; M. Ali; A. Berardelli; RB. Daroff; G. Defazio; M. Delong; D. Eidelberg; C. Evinger, Update on blepharospasm: report from the BEBRF International Workshop., in Neurology, vol. 71, n. 16, ottobre 2008, pp. 1275-82, DOI:10.1212/01.wnl.0000327601.46315.85, PMID 18852443.
SA. Schellini, O. Matai; TZ. Igami; CR. Padovani; CP. Padovani, [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review], in Arq Bras Oftalmol, vol. 69, n. 1, pp. 23-6, PMID 16491229.
A. Esteban-García, [Blepharospasm and blepharocolysis. Different sides of the same coin], in Rev Neurol, vol. 40, n. 5, pp. 298-302, PMID 15782362.
NC. Tan, LL. Chan; EK. Tan, Hemifacial spasm and involuntary facial movements., in QJM, vol. 95, n. 8, agosto 2002, pp. 493-500, PMID 12145388.
Y. Real Martínez, M. Ibáñez Moya; A. Pérez Mota, [Megarectum and anismus: a cause of constipation], in Rev Esp Enferm Dig, vol. 99, n. 6, giugno 2007, pp. 352-3, PMID 17883300.
E. Tolosa, Y. Compta, Dystonia in Parkinson's disease., in J Neurol, 253 Suppl 7, dicembre 2006, pp. VII7-13, DOI:10.1007/s00415-006-7003-6, PMID 17131231.
A. Traba López, A. Esteban, Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology., in Neurophysiol Clin, vol. 31, n. 4, agosto 2001, pp. 220-9, PMID 11596529.
R. Tim, JM. Massey, Botulinum toxin therapy for neurologic disorders., in Postgrad Med, vol. 91, n. 6, maggio 1992, pp. 327-32, 334, PMID 1579537.
JS. Yoon, JC. Kim; SY. Lee, Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm., in Korean J Ophthalmol, vol. 23, n. 3, settembre 2009, pp. 137-41, DOI:10.3341/kjo.2009.23.3.137, PMID 19794937.
RM. Zagui, S. Matayoshi; FC. Moura, [Adverse effects associated with facial application of botulinum toxin: a systematic review with meta-analysis], in Arq Bras Oftalmol, vol. 71, n. 6, pp. 894-901, PMID 19169530.
R. Laskawi, The use of botulinum toxin in head and face medicine: an interdisciplinary field., in Head Face Med, vol. 4, 2008, p. 5, DOI:10.1186/1746-160X-4-5, PMID 18331633.
S. Badarny, Z. Susel; S. Honigman, Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox., in Isr Med Assoc J, vol. 10, n. 7, luglio 2008, pp. 520-2, PMID 18751631.
CG. Lasalvia, Lde S. Pereira; MC. da Cunha; SP. Kitadai, [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm], in Arq Bras Oftalmol, vol. 69, n. 5, pp. 701-5, PMID 17187139.
S. Koh, J. Hosohata; Y. Tano, Bilateral upper eyelid ectropion associated with blepharospasm., in Br J Ophthalmol, vol. 90, n. 11, novembre 2006, pp. 1437-8, DOI:10.1136/bjo.2006.097089, PMID 17057180.
C. Colosimo, M. Chianese; M. Giovannelli; MF. Contarino; AR. Bentivoglio, Botulinum toxin type B in blepharospasm and hemifacial spasm., in J Neurol Neurosurg Psychiatry, vol. 74, n. 5, maggio 2003, p. 687, PMID 12700325.
J. Horwath-Winter, J. Bergloeff; I. Floegel; EM. Haller-Schober; O. Schmut, Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye., in Br J Ophthalmol, vol. 87, n. 1, gennaio 2003, pp. 54-6, PMID 12488263.
N. Guépratte, DA. Lebuisson, [Botulinum toxin in ophthalmology], in J Fr Ophtalmol, vol. 24, n. 9, novembre 2001, pp. 1010-2, PMID 11912832.
Bhatia MS, Gupta R, Essential blepharospasm responding to haloperidol, in J Neuropsychiatry Clin Neurosci, vol. 18, n. 4, 2006, pp. 554–6, DOI:10.1176/appi.neuropsych.18.4.554, PMID 17135386.
JA. Mauriello, S. Dhillon; T. Leone; B. Pakeman; R. Mostafavi; MC. Yepez, Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years., in Br J Ophthalmol, vol. 80, n. 12, dicembre 1996, pp. 1073-6, PMID 9059273.
J. Ananth, E. Edelmuth; B. Dargan, Meige's syndrome associated with neuroleptic treatment., in Am J Psychiatry, vol. 145, n. 4, aprile 1988, pp. 513-5, PMID 2894781.
G. Ransmayr, B. Kleedorfer; RA. Dierckx; W. Poewe; GW. Kemmler; F. Gerstenbrand, Pharmacological study in Meige's syndrome with predominant blepharospasm., in Clin Neuropharmacol, vol. 11, n. 1, febbraio 1988, pp. 68-76, PMID 3280128.
L. Parisi, L. Sanarelli; R. Mariorenzi; G. Valente; C. Dell'Anna; G. Amabile, [3 cases of essential blepharospasm: pathogenetic problems correlated], in Riv Neurol, vol. 56, n. 5, pp. 286-92, PMID 2883717.
ES. Tolosa, C. Lai, Meige disease: striatal dopaminergic preponderance., in Neurology, vol. 29, n. 8, agosto 1979, pp. 1126-30, PMID 379689.

oadoi.org

K. Tanner, N. Roy; RM. Merrill; K. Kimber; C. Sauder; DR. Houtz; D. Doman; ME. Smith, Risk and Protective Factors for Spasmodic Dysphonia: A Case-Control Investigation., in J Voice, febbraio 2010, DOI:10.1016/j.jvoice.2009.09.004, PMID 20171836.
J. Xiao, Y. Zhao; RW. Bastian; JS. Perlmutter; BA. Racette; SD. Tabbal; M. Karimi; RC. Paniello; ZK. Wszolek; RJ. Uitti; JA. Van Gerpen, Novel THAP1 sequence variants in primary dystonia., in Neurology, vol. 74, n. 3, gennaio 2010, pp. 229-38, DOI:10.1212/WNL.0b013e3181ca00ca, PMID 20083799.
MA. van Steensel, RJ. Damstra; MV. Heitink; RS. Bladergroen; J. Veraart; PM. Steijlen; M. van Geel, Novel missense mutations in the FOXC2 gene alter transcriptional activity., in Hum Mutat, vol. 30, n. 12, dicembre 2009, pp. E1002-9, DOI:10.1002/humu.21127, PMID 19760751.
MS. LeDoux, Meige syndrome: what's in a name?, in Parkinsonism Relat Disord, vol. 15, n. 7, agosto 2009, pp. 483-9, DOI:10.1016/j.parkreldis.2009.04.006, PMID 19457699.
G. Defazio, M. Matarin; EL. Peckham; D. Martino; EM. Valente; A. Singleton; A. Crawley; MS. Aniello; F. Brancati; G. Abbruzzese; P. Girlanda, The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm., in Mov Disord, vol. 24, n. 4, marzo 2009, pp. 613-6, DOI:10.1002/mds.22471, PMID 19202559.
M. Hallett, C. Evinger; J. Jankovic; M. Stacy; M. Ali; A. Berardelli; RB. Daroff; G. Defazio; M. Delong; D. Eidelberg; C. Evinger, Update on blepharospasm: report from the BEBRF International Workshop., in Neurology, vol. 71, n. 16, ottobre 2008, pp. 1275-82, DOI:10.1212/01.wnl.0000327601.46315.85, PMID 18852443.
E. Tolosa, Y. Compta, Dystonia in Parkinson's disease., in J Neurol, 253 Suppl 7, dicembre 2006, pp. VII7-13, DOI:10.1007/s00415-006-7003-6, PMID 17131231.
JS. Yoon, JC. Kim; SY. Lee, Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm., in Korean J Ophthalmol, vol. 23, n. 3, settembre 2009, pp. 137-41, DOI:10.3341/kjo.2009.23.3.137, PMID 19794937.
R. Laskawi, The use of botulinum toxin in head and face medicine: an interdisciplinary field., in Head Face Med, vol. 4, 2008, p. 5, DOI:10.1186/1746-160X-4-5, PMID 18331633.
Bhatia MS, Gupta R, Essential blepharospasm responding to haloperidol, in J Neuropsychiatry Clin Neurosci, vol. 18, n. 4, 2006, pp. 554–6, DOI:10.1176/appi.neuropsych.18.4.554, PMID 17135386.

web.archive.org

The National Institutes of Health (NIH) Consensus Development Program: Clinical Use of Botulinum Toxin, su consensus.nih.gov. URL consultato il 5 settembre 2010 (archiviato dall'url originale il 5 dicembre 2010).
Oral Medications for Treatment of Blepharospasm and other Cranial Dystonias, su blepharospasm.org (archiviato dall'url originale il 25 settembre 2011).